Hansoh Pharmac Hd 00001 Stock Total Asset
3KY Stock | EUR 2.14 0.02 0.93% |
HANSOH PHARMAC HD 00001 fundamentals help investors to digest information that contributes to HANSOH PHARMAC's financial success or failures. It also enables traders to predict the movement of HANSOH Stock. The fundamental analysis module provides a way to measure HANSOH PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HANSOH PHARMAC stock.
HANSOH |
HANSOH PHARMAC HD 00001 Company Total Asset Analysis
HANSOH PHARMAC's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition |
Based on the latest financial disclosure, HANSOH PHARMAC HD 00001 has a Total Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The total asset for all Germany stocks is 100.0% higher than that of the company.
HANSOH Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HANSOH PHARMAC's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HANSOH PHARMAC could also be used in its relative valuation, which is a method of valuing HANSOH PHARMAC by comparing valuation metrics of similar companies.HANSOH PHARMAC is currently under evaluation in total asset category among its peers.
HANSOH Fundamentals
Return On Equity | 0.14 | |||
Return On Asset | 0.063 | |||
Profit Margin | 0.27 % | |||
Operating Margin | 0.28 % | |||
Shares Outstanding | 5.92 B | |||
Shares Owned By Insiders | 81.92 % | |||
Shares Owned By Institutions | 7.99 % | |||
Price To Earning | 38.60 X | |||
Revenue | 9.97 B | |||
Gross Profit | 9.06 B | |||
EBITDA | 3.02 B | |||
Net Income | 2.57 B | |||
Cash And Equivalents | 13.73 B | |||
Cash Per Share | 2.32 X | |||
Total Debt | 92.75 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 6.43 X | |||
Book Value Per Share | 3.57 X | |||
Cash Flow From Operations | 2.39 B | |||
Earnings Per Share | 0.06 X | |||
Number Of Employees | 10.78 K | |||
Beta | 0.57 | |||
Market Capitalization | 11.47 B | |||
Z Score | 73.8 | |||
Annual Yield | 0.01 % | |||
Last Dividend Paid | 0.12 |
About HANSOH PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HANSOH PHARMAC HD 00001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HANSOH PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.